Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879913 | 0.73 | MAPK1 (0.39) | HDAC4OPRL1PDE10A | |
| SCHEMBL19706489 | 0.72 | OPRM1 (0.49) | OPRL1OPRM1 | |
| SCHEMBL22950609 | 0.69 | PKM (0.32) | — | |
| SCHEMBL15353373 | 0.69 | HDAC4 (0.41) | HDAC4OPRL1PDE10A | |
| SCHEMBL11086191 | 0.69 | MAPK1 (0.39) | HDAC4OPRL1PDE10A | |
| SCHEMBL26365349 | 0.69 | OPRL1 (0.50) | HDAC4OPRL1PDE10A | |
| SCHEMBL1713163 | 0.69 | HDAC4 (0.38) | HDAC4OPRL1PDE10A | |
| SCHEMBL587475 | 0.69 | HDAC4 (0.38) | HDAC4OPRL1PDE10A | |
| SCHEMBL19336398 | 0.69 | HDAC4 (0.34) | HDAC4OPRL1PDE10A | |
| SCHEMBL24958720 | 0.69 | OPRM1 (0.33) | OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | HDAC4 2923/4885OPRL1 2245/4885OPRM1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.